Increased nuchal translucency can be ascertained using transverse planes


      The detection of increased nuchal translucency is crucial for the assessment risk of aneuploidies and other fetal anomalies.


      This study aimed to investigate the ability of a transverse view of the fetal head to detect increased fetal nuchal translucency at 11 to 13 weeks of gestation.

      Study Design

      This was a prospective study enrolling a nonconsecutive series of women who attended our outpatient clinic from January 2020 to April 2021 for combined screening and were examined by operators certified by the Fetal Medicine Foundation. In each patient, nuchal translucency measurements were obtained both from a median sagittal view and from a transverse view. A second sonologist blinded to the results of the first examination obtained another measurement to assess intermethod and interobsever reproducibility.


      A total of 1023 women were enrolled. An excellent correlation was found between sagittal and transverse nuchal translucency measurements, with a mean difference of 0.01 mm (95% confidence interval, −0.01 to 0.02). No systematic difference was found between the 2 techniques. The inter-rater reliability (intraclass correlation coefficient, 0.957; 95% confidence interval, 0.892–0.983) and intrarater reliability (intraclass correlation coefficient, 0.976; 95% confidence interval, 0.941–0.990) of axial measurements were almost perfect. Transverse measurements of 3.0 mm identified all cases with sagittal measurements of ≥3.0 with a specificity of 99.7%; transverse measurements of >3.2 mm identified all cases with sagittal measurements of 3.5 mm with a specificity of 99.7%. The time required to obtain transverse nuchal translucency measurements was considerably shorter than for sagittal measurements, particularly when the fetus had an unfavorable position.


      When the sonogram is performed by an expert sonologist, the difference in nuchal translucency measurement obtained with a transverse or sagittal plane is minimal. Increased nuchal translucency can be reliably identified by using transverse views, and in some cases, this may technically be advantageous.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hui L.
        • Hutchinson B.
        • Poulton A.
        • Halliday J.
        Population-based impact of noninvasive prenatal screening on screening and diagnostic testing for fetal aneuploidy.
        Genet Med. 2017; 19: 1338-1345
        • Nicolaides K.H.
        Screening for fetal aneuploidies at 11 to 13 weeks.
        Prenat Diagn. 2011; 31: 7-15
        • Nicolaides K.H.
        • Azar G.
        • Byrne D.
        • Mansur C.
        • Marks K.
        Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.
        BMJ. 1992; 304: 867-869
        • Pandya P.P.
        • Snijders R.J.
        • Johnson S.P.
        • De Lourdes Brizot M.
        • Nicolaides K.H.
        Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation.
        Br J Obstet Gynaecol. 1995; 102: 957-962
        • Wright D.
        • Syngelaki A.
        • Bradbury I.
        • Akolekar R.
        • Nicolaides K.H.
        First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
        Fetal Diagn Ther. 2014; 35: 118-126
        • Kagan K.O.
        • Wright D.
        • Baker A.
        • Sahota D.
        • Nicolaides K.H.
        Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
        Ultrasound Obstet Gynecol. 2008; 31: 618-624
        • ACOG Committee on Practice Bulletins
        ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities.
        Obstet Gynecol. 2007; 109: 217-227
        • Kagan K.O.
        • Avgidou K.
        • Molina F.S.
        • Gajewska K.
        • Nicolaides K.H.
        Relation between increased fetal nuchal translucency thickness and chromosomal defects.
        Obstet Gynecol. 2006; 107: 6-10
        • Minnella G.P.
        • Crupano F.M.
        • Syngelaki A.
        • Zidere V.
        • Akolekar R.
        • Nicolaides K.H.
        Diagnosis of major heart defects by routine first-trimester ultrasound examination: association with increased nuchal translucency, tricuspid regurgitation and abnormal flow in ductus venosus.
        Ultrasound Obstet Gynecol. 2020; 55: 637-644
        • Nicolaides K.H.
        Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
        Am J Obstet Gynecol. 2004; 191: 45-67
        • Nicolaides K.H.
        • Heath V.
        • Cicero S.
        Increased fetal nuchal translucency at 11-14 weeks.
        Prenat Diagn. 2002; 22: 308-315
        • Pandya P.P.
        • Kondylios A.
        • Hilbert L.
        • Snijders R.J.
        • Nicolaides K.H.
        Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency.
        Ultrasound Obstet Gynecol. 1995; 5: 15-19
        • Souka A.P.
        • Von Kaisenberg C.S.
        • Hyett J.A.
        • Sonek J.D.
        • Nicolaides K.H.
        Increased nuchal translucency with normal karyotype.
        Am J Obstet Gynecol. 2005; 192: 1005-1021
        • Pandya P.P.
        • Brizot M.L.
        • Kuhn P.
        • Snijders R.J.
        • Nicolaides K.H.
        First-trimester fetal nuchal translucency thickness and risk for trisomies.
        Obstet Gynecol. 1994; 84: 420-423
        • Baer R.J.
        • Norton M.E.
        • Shaw G.M.
        • et al.
        Risk of selected structural abnormalities in infants after increased nuchal translucency measurement.
        Am J Obstet Gynecol. 2014; 211: 675.e1-675.e19
        • Liao Y.
        • Wen H.
        • Ouyang S.
        • et al.
        Routine first-trimester ultrasound screening using a standardized anatomical protocol.
        Am J Obstet Gynecol. 2021; 224: 396.e1-396.e15
        • Makrydimas G.
        • Sotiriadis A.
        • Huggon I.C.
        • et al.
        Nuchal translucency and fetal cardiac defects: a pooled analysis of major fetal echocardiography centers.
        Am J Obstet Gynecol. 2005; 192: 89-95
        • Gil M.M.
        • Accurti V.
        • Santacruz B.
        • Plana M.N.
        • Nicolaides K.H.
        Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis.
        Ultrasound Obstet Gynecol. 2017; 50: 302-314
        • Bardi F.
        • Bosschieter P.
        • Verheij J.
        • et al.
        Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?.
        Prenat Diagn. 2020; 40: 197-205
        • Vora N.L.
        • Robinson S.
        • Hardisty E.E.
        • Stamilio D.M.
        Utility of ultrasound examination at 10-14 weeks prior to cell-free DNA screening for fetal aneuploidy.
        Ultrasound Obstet Gynecol. 2017; 49: 465-469
        • Vogel I.
        • Petersen O.B.
        Prenatal screening for atypical chromosomal abnormalities: past or future?.
        Ultrasound Obstet Gynecol. 2018; 51: 434-435
        • Evans M.I.
        • Andriole S.
        • Curtis J.
        • Evans S.M.
        • Kessler A.A.
        • Rubenstein A.F.
        The epidemic of abnormal copy number variant cases missed because of reliance upon noninvasive prenatal screening.
        Prenat Diagn. 2018; 38: 730-734
        • Han C.S.
        • Platt L.D.
        Noninvasive prenatal testing: need for informed enthusiasm.
        Am J Obstet Gynecol. 2014; 211: 577-580
        • Norton M.E.
        • Biggio J.R.
        • Kuller J.A.
        • Blackwell S.C.
        • Blackwell S.C.
        • Society for Maternal-Fetal Medicine
        The role of ultrasound in women who undergo cell-free DNA screening.
        Am J Obstet Gynecol. 2017; 216: B2-B7
        • Srebniak M.I.
        • de Wit M.C.
        • Diderich K.E.
        • et al.
        Enlarged NT (≥3.5 mm) in the first trimester - not all chromosome aberrations can be detected by NIPT.
        Mol Cytogenet. 2016; 9: 69
        • Petersen O.B.
        • Smith E.
        • Van Opstal D.
        • et al.
        Nuchal translucency of 3.0-3.4 mm an indication for NIPT or microarray? Cohort analysis and literature review.
        Acta Obstet Gynecol Scand. 2020; 99: 765-774
        • Hui L.
        • Pynaker C.
        • Bonacquisto L.
        • et al.
        Reexamining the optimal nuchal translucency cutoff for diagnostic testing in the cell-free DNA and microarray era: results from the Victorian Perinatal Record Linkage study.
        Am J Obstet Gynecol. 2021; 225: 527.e1-527.e12
        • Hui L.
        • Palma-Dias R.
        • da Silva Costa F.
        The diagnosis of an increased nuchal translucency remains a persistent clinical dilemma that deserves a rational approach.
        Am J Obstet Gynecol. 2021; 225: 464-465
        • Ericsson O.
        • Ahola T.
        • Dahl F.
        • et al.
        Clinical validation of a novel automated cell-free DNA screening assay for trisomies 21, 13, and 18 in maternal plasma.
        Prenat Diagn. 2019; 39: 1011-1015
        • Salomon L.J.
        • Alfirevic Z.
        • Bilardo C.M.
        • et al.
        ISUOG practice guidelines: performance of first-trimester fetal ultrasound scan.
        Ultrasound Obstet Gynecol. 2013; 41: 102-113
        • Malinger G.
        • Paladini D.
        • Haratz K.K.
        • Monteagudo A.
        • Pilu G.L.
        • Timor-Tritsch I.E.
        ISUOG Practice Guidelines (updated): sonographic examination of the fetal central nervous system. Part 1: performance of screening examination and indications for targeted neurosonography.
        Ultrasound Obstet Gynecol. 2020; 56: 476-484
        • Paladini D.
        • Malinger G.
        • Birnbaum R.
        • et al.
        ISUOG Practice Guidelines (updated): sonographic examination of the fetal central nervous system. Part 2: performance of targeted neurosonography.
        Ultrasound Obstet Gynecol. 2021; 57: 661-671
        • Nicolaides K.H.
        • Snijders R.J.
        • Gosden C.M.
        • Berry C.
        • Campbell S.
        Ultrasonographically detectable markers of fetal chromosomal abnormalities.
        Lancet. 1992; 340: 704-707
        • Li Y.L.
        • Li D.Z.
        Is there a role for nuchal translucency in the detection of rare chromosomal abnormalities in the era of noninvasive prenatal testing?.
        Am J Obstet Gynecol. 2021; 225: 463-464